![6-Bromo-4-hydroxy-pyrazolo[1,5-a]pyridine-3-carbonitrile](https://ecdn6.globalso.com/upload/p/1956/image_product/2024-08/photo-network_400282730_medical-cell-experiment-non-enterprise-commercial-use.jpg)
Pharmaceutical intermediates
![2-Pyridinecarboxylic acid, 5-amino-6-[[(2S)-2-oxetanylmethyl]amino]-, methyl ester](https://ecdn6.globalso.com/upload/p/1956/image_product/2024-08/2230200-78-7.jpg)
![Methanesulfonic acid, 1,1,1-trifluoro-, 6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl ester](https://ecdn6.globalso.com/upload/p/1956/image_product/2024-08/2222756-23-0.jpg)
![2-[2-(4-benzoylphenoxy)ethoxy]ethyl methacrylate](https://ecdn6.globalso.com/upload/p/1956/image_product/2024-08/2149581-44-0.jpg)
![Pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-methoxy-](https://ecdn6.globalso.com/upload/p/1956/image_product/2024-08/2110326-74-2.jpg)
0102030405
6-Bromo-4-hydroxy-pyrazolo[1,5-a]pyridine-3-carbonitrile
Usage
6-Bromo-4-hydroxy-pyrazolo[1,5-a]pyridine-3-carbonitrile is a pharmaceutical intermediate used in the preparation of Selpercatinib, an FDA-approved drug for the treatment of RET-positive advanced non-small cell lung cancer (NSCLC), thyroid cancer and certain other cancers
Structural Diagram
